Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL cholesterol with a strong safety profile. ・The company plans to advance the ...

Beyond its refreshing sweetness and tropical flavour, guava is emerging as a nutritional powerhouse with benefits that reach far beyond taste. Packed with fibre, antioxidants and essential vitamins, ...

Pharmaceutical maker Merck presented its findings on the drug "Enlicitide" at an American Heart Association Conference this ...

A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...

Guidelines disagree on whether children should be screened to identify familial hypercholesterolemia, which is associated ...

In the United States, 1 in every 250 people has inherited a genetic variant that leads to dangerously high cholesterol levels ...

A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for ...

More than 140,000 bottles of a popular drug commonly prescribed to reduce cholesterol have been recalled for a defect that could make the medication less effective.

Several lots of the cholesterol medication atorvastatin were recalled after failed dissolution tests, according to the FDA.

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...